Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report.

Acalculous cholecystitis COVID 19 Dysregulated immune response Novel coronavirus disease 2019 SARS-CoV-2

Journal

Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 23 09 2020
revised: 07 11 2020
accepted: 07 11 2020
entrez: 23 11 2020
pubmed: 24 11 2020
medline: 24 11 2020
Statut: ppublish

Résumé

Novel Coronavirus disease 2019 or COVID-19 has rapidly spread throughout the world and has become an unprecedented pandemic. It has a vast spectrum of clinical presentations and can affect various organs. Rarely, it has been reported to cause acalculous cholecystitis in a non ICU setting patient. Here we report a rare association of COVID 19 with acalculous cholecystitis in a 40 years old healthy woman. She developed fever, malaise, generalized body weakness, and right hypochondrial pain after fourteen days of COVID 19 infection, raising the possibility of Post COVID dysregulated immune response resulting in acalculous cholecystitis. She was managed conservatively with broad spectrum antibiotics. Acalculous cholecystitis primarily occurs due to the gall bladder's hypomotility and most commonly seen in critically ill patients such as severe burns, mechanically ventilated patients, and prolonged parenteral nutrition. The management depends upon treating the underlying pathology and, in some severe cases, may need surgical intervention as well. Up to our knowledge, COVID 19, causing acalculous cholecystitis, is a rare association described only in a few critically ill patients but not in young, healthy patients. It can be attributed to the body's dysregulated immunological response against the virus resulting in systemic inflammation. Currently, there is are no clear guidelines for managing acute cholecystitis in COVID-19 patients. It depends on the patient's clinical state and disease severity. We aim to highlight the importance of early diagnosis and management in such clinical scenarios to avoid fatal complications.

Identifiants

pubmed: 33224493
doi: 10.1016/j.amsu.2020.11.031
pii: S2049-0801(20)30458-1
pmc: PMC7664478
doi:

Types de publication

Case Reports

Langues

eng

Pagination

434-437

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

None of the authors had any personal or financial conflicts of interest.

Références

Am J Emerg Med. 2020 May 23;:
pubmed: 32471782
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
J Card Fail. 2020 Jul;26(7):639
pubmed: 32525070
Updates Surg. 2020 Sep;72(3):917-919
pubmed: 32458339
Ann Med Surg (Lond). 2020 Oct;58:73-75
pubmed: 32895611
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Int J Antimicrob Agents. 2020 Aug;56(2):106024
pubmed: 32450197
World J Emerg Surg. 2020 Jul 2;15(1):43
pubmed: 32615987

Auteurs

Shahda Mohamed Alhassan (SM)

Hamad Medical Corporation, Doha, Qatar.

Phool Iqbal (P)

Hamad Medical Corporation, Doha, Qatar.

Lubna Fikrey (L)

Hamad Medical Corporation, Doha, Qatar.

Mohanad Ibrahim Mohamed Ibrahim (MI)

Hamad Medical Corporation, Doha, Qatar.

Muhammad Sohaib Qamar (MS)

Ozarks Medical Center, Missouri, USA.

Masautso Chaponda (M)

Hamad Medical Corporation, Doha, Qatar.
Communicable Disease Center, Doha, Qatar.

Waqar Munir (W)

Hamad Medical Corporation, Doha, Qatar.
Communicable Disease Center, Doha, Qatar.

Classifications MeSH